Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports First Quarter of 2011 Results


      News provided by

      Cambrex Corporation

      May 05, 2011, 04:10 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., May 5, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports first quarter results for the period ended March 31, 2011.

      Highlights

      • Reported sales increased by 9.8%, and excluding the impact of foreign currency, sales increased 6.9% compared to first quarter of 2010.
      • EBITDA was $11.0 million in the first quarter of 2011, an increase of 21.3% compared to $9.1 million in the first quarter of 2010.
      • Debt, net of cash was $82.6 million at the end of the first quarter of 2011, an improvement of $3.7 million during the quarter which includes $0.3 million of M&A payments and a positive $2.0 million currency impact on foreign cash balances.

      First Quarter of 2011 Operating Results – Continuing Operations

      First quarter of 2011 sales of $61.7 million were 9.8% higher than the first quarter of 2010.  Excluding a 2.9% favorable impact of foreign exchange, reflecting a weaker U.S. dollar, sales increased 6.9%.  The increase is primarily due to higher sales of an active pharmaceutical ingredient ("API") to a customer who resolved their supply chain disruption which had reduced Cambrex's sales volumes in the first quarter of 2010, higher volumes of generic APIs and increased volumes for a recently approved product.  These increases were partially offset by lower custom development and drug delivery shipments and lower pricing across several product categories.  

      First quarter of 2011 Gross Margin increased to 28.3% from 25.8% during the first quarter of 2010, with foreign currency unfavorably impacting gross margin by 2.5% in the first quarter of 2011.  Gross margins were positively impacted by higher sales and production volumes and lower production costs, partially offset by lower pricing.  

      Selling, General and Administrative Expenses in the first quarter of 2011 were $9.1 million compared to $8.8 million in the same period last year.  The increase is a result of unfavorable foreign exchange.

      Research and Development ("R&D") Expenses increased to $3.1 million in the first quarter of 2011 from $2.0 million in the first quarter of 2010 primarily due to the March 2010 acquisition of IEP, the development of new products and technology platforms and reduced utilization of certain R&D personnel on revenue generating custom development projects resulting in these costs being expensed rather than absorbed into cost of sales or inventory.

      Operating Profit increased to $5.3 million in the first quarter of 2011 from $3.7 million in the first quarter of 2010.  The increase in Operating Profit was driven primarily by higher gross profits partially offset by higher operating expenses as described above.

      Net Interest Expense decreased to $0.6 million in the first quarter of 2011 from $1.2 million in first quarter of 2010.  This decrease is primarily due to the maturing of the Company's higher fixed interest rate swaps in October 2010.

      The Provision for Income Taxes totaled $1.5 million in the first quarter of 2011.  The Company's effective tax rate has been and is expected to remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits where there has been a recent history of losses, primarily in the U.S.

      Income from continuing operations for the first quarter of 2011 was $2.9 million or $0.10 per share compared to $1.7 million or $0.06 per share in the first quarter of 2010.

      Capital expenditures and depreciation for the first quarter of 2011 were $1.7 million and $5.6 million compared to $2.7 million and $5.4 million in the first quarter of 2010, respectively.

      Steven M. Klosk, President and Chief Executive Officer, said, "We are pleased with our first quarter performance with sales volumes significantly higher year over year.  In addition to the increases in sales volumes for some of our larger custom manufacturing products, we continue to see strong orders for our generic APIs.  Cambrex Zenara is off to a positive start and has been asked to increase production as part of their customer's launch of a leading nicotine replacement therapy product in India."

      Guidance – Continuing Operations

      The Company continues to expect that sales for 2011, excluding the impact of foreign currency, will increase between 3% and 7% versus 2010, and that full year 2011 EBITDA will be between $43 and $49 million.  EBITDA guidance is for continuing operations and excludes the impact of any M&A or restructuring activities.  The above guidance does not reflect Cambrex Zenara, which is accounted for using the equity method, and as such is not consolidated into the Company's results.  Cambrex's income statement reflects 51% of Cambrex Zenara's net results as Equity in Losses of Partially-Owned Affiliate.  For 2011, Cambrex Zenara is expected to have revenues in the low to mid single digit millions and a small EBITDA loss.

      Capital expenditures are expected to be approximately $14 to $17 million and depreciation is expected to be $21 to $23 million in 2011.

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's first quarter 2011 Form 10-Q is filed with the SEC.

      Conference Call and Webcast

      The Conference Call to discuss first quarter of 2011 results will begin at 8:30 a.m. Eastern Time on Friday, May 6, 2011 and last approximately 45 minutes.  Those wishing to participate should call 1-888-299-7230 for domestic and +1-719-325-2168 for international.  Please use the pass code 7839366 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days following the conference call.  A telephone replay of the conference call will be available through Friday, May 13, 2011 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 7839366 to access the replay.  

      Forward Looking Statements

      This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2010, captioned "Risk Factors," or otherwise described in the Company's filings with the Securities and Exchange Commission, as well as any cautionary language in the Company's Annual Report on Form 10-K for the period ended December 31, 2010, provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectable receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, and the Company's ability to receive regulatory approvals for its products.

      For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2010 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  

      About Cambrex

      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.  

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended March 31, 2011 and 2010

      (in thousands)













      2011


      2010





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      61,654




      $

      56,155



          Commissions, Allowances and Rebates


      291





      336



      Net Sales


      61,363





      55,819













          Other


      (778)





      274













      Net Revenues


      60,585





      56,093













          Cost of Goods Sold


      43,130


      70.0%



      41,600


      74.1%











      Gross Profit


      17,455


      28.3%



      14,493


      25.8%











      Operating Expenses










          Selling, General and Administrative Expenses


      9,088


      14.7%



      8,796


      15.7%

          Research and Development Expenses


      3,060


      5.0%



      1,985


      3.5%

      Total Operating Expenses


      12,148


      19.7%



      10,781


      19.2%











      Operating Profit


      5,307


      8.6%



      3,712


      6.6%











      Other Expenses/(Income):










          Interest Expense, net


      573





      1,198



          Other (Income)/Expenses, net


      (3)





      3



          Equity in Losses of Partially-Owned Affiliate


      364





      -













      Income Before Income Taxes


      4,373


      7.1%



      2,511


      4.5%











          Provision for Income Taxes


      1,518





      828













      Income from Continuing Operations

      $

      2,855


      4.6%


      $

      1,683


      3.0%











      Loss from Discontinued Operations, Net of Tax


      (146)





      -













      Net Income

      $

      2,709


      4.4%


      $

      1,683


      3.0%











      Basic Earnings/(Loss) per Share of Common Stock:










        Income from Continuing Operations


      $   0.10





      $   0.06



        Loss from Discontinued Operations, Net of Tax


      $ (0.01)





      $       -



        Net Income


      $   0.09





      $   0.06













      Diluted Earnings/(Loss) per Share of Common Stock:










        Income from Continuing Operations


      $   0.10





      $   0.06



        Loss from Discontinued Operations, Net of Tax


      $ (0.01)





      $       -



        Net Income


      $   0.09





      $   0.06













      Weighted Average Shares Outstanding










          Basic


      29,448





      29,315



          Diluted


      29,518





      29,374





      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of March 31, 2011 and December 31, 2010

      (in thousands)















      March 31,



      December 31,

      Assets


      2011



      2010







      Cash and Cash Equivalents

      $

      35,342


      $

      29,614

      Trade Receivables, net


      38,458



      39,025

      Inventories, net


      67,675



      61,408

      Prepaid Expenses and Other Current Assets


      5,043



      5,082

       Total Current Assets


      146,518



      135,129







      Property, Plant and Equipment, net


      154,329



      150,483

      Goodwill


      39,616



      37,694

      Intangibles Assets, net


      4,883



      4,687

      Investment in Partially-Owned Affiliate


      19,344



      19,709

      Other Non-Current Assets


      3,590



      4,049







       Total Assets

      $

      368,280


      $

      351,751







      Liabilities and Stockholders' Equity












      Accounts Payable

      $

      19,375


      $

      19,480

      Accrued Expenses and Other Current Liabilities


      36,022



      33,503

       Total Current Liabilities


      55,397



      52,983







      Long-term Debt


      117,900



      115,900

      Deferred Income Taxes


      18,489



      17,893

      Accrued Pension and Postretirement Benefits


      41,262



      43,921

      Other Non-Current Liabilities


      13,310



      13,419







       Total Liabilities

      $

      246,358


      $

      244,116







       Stockholders’ Equity

      $

      121,922


      $

      107,635







       Total Liabilities and Stockholders’ Equity

      $

      368,280


      $

      351,751



      CAMBREX CORPORATION

      Reconciliation of EBITDA

      For the Quarters Ended March 31, 2011 and 2010

      (in thousands)









      First Quarter 2011



      First Quarter 2010








      Operating Profit

      $

      5,307



      $

      3,712








      Depreciation and Amortization


      5,725




      5,384








      EBITDA

      $

      11,032



      $

      9,096



      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.